title: Radiotherapy technical considerations in the management of locally advanced pancreatic cancer: American-French consensus recommendations.
abstract: Pancreatic carcinoma is a leading cause of cancer-related mortality. Approximately 30% of pancreatic cancer patients present with locally advanced, unresectable nonmetastatic disease. For these patients, two therapeutic options exist: systemic chemotherapy or chemoradiotherapy. Within this context, the optimal technique for pancreatic irradiation is not clearly defined. A search to identify relevant studies was undertaken using the Medline database. All Phase III randomized trials evaluating the modalities of radiotherapy in locally advanced pancreatic cancer were included, as were some noncontrolled Phase II and retrospective studies. An expert panel convened with members of the Radiation Therapy Oncology Group and GERCOR cooperative groups to review identified studies and prepare the guidelines. Each member of the working group independently evaluated five endpoints: total dose, target volume definition, radiotherapy planning technique, dose constraints to organs at risk, and quality assurance. Based on this analysis of the literature, we recommend either three-dimensional conformal radiation therapy or intensity-modulated radiation therapy to a total dose of 50 to 54 Gy at 1.8 to 2 Gy per fraction. We propose gross tumor volume identification to be followed by an expansion of 1.5 to 2 cm anteriorly, posteriorly, and laterally, and 2 to 3 cm craniocaudally to generate the planning target volume. The craniocaudal margins can be reduced with the use of respiratory gating. Organs at risk are liver, kidneys, spinal cord, stomach, and small bowel. Stereotactic body radiation therapy should not be used for pancreatic cancer outside of clinical trials. Radiotherapy quality assurance is mandatory in clinical trials. These consensus recommendations are proposed for use in the development of future trials testing new chemotherapy combinations with radiotherapy. Not all of these recommendations will be appropriate for trials testing radiotherapy dose or dose intensity concepts.
authors: Department of Radiation Oncology, Tenon Hospital, APHP, University Paris VI, Paris, France. florence.huguet@tnn.aphp.fr
authors: Florence
authors: F
authors: Huguet
authors: Karyn A
authors: KA
authors: Goodman
authors: David
authors: D
authors: Azria
authors: Severine
authors: S
authors: Racadot
authors: Ross A
authors: RA
authors: Abrams
mesh_terms: D059248:Chemoradiotherapy / Q000379:methods* / Q000592:standards; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D005602:France; D006801:Humans; D007421:Intestine, Small / Q000000981:diagnostic imaging / Q000528:radiation effects; D007668:Kidney / Q000000981:diagnostic imaging / Q000528:radiation effects; D008099:Liver / Q000000981:diagnostic imaging / Q000528:radiation effects; D058958:Organs at Risk / Q000000981:diagnostic imaging / Q000528:radiation effects; D010190:Pancreatic Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy*; D011785:Quality Assurance, Health Care; D011859:Radiography; D011879:Radiotherapy Dosage; D011880:Radiotherapy Planning, Computer-Assisted / Q000379:methods*; D020266:Radiotherapy, Conformal / Q000379:methods*; D050397:Radiotherapy, Intensity-Modulated / Q000379:methods; D016032:Randomized Controlled Trials as Topic; D013116:Spinal Cord / Q000000981:diagnostic imaging / Q000528:radiation effects; D013270:Stomach / Q000000981:diagnostic imaging / Q000528:radiation effects; D047368:Tumor Burden; D014481:United States